16 Febbraio 2022
K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio, G Gualdi, L Bianchi, L Stingeni

A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis

J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e111-e113

Key messages

  • Aggiornamento a 52 settimane di un’esperienza multicentrica real-life sull’efficacia e la sicurezza di risankizumab nella psoriasi.


The long-term efficacy and safety of the IL-23 inhibitor risankizumab has been demonstrated in clinical trials, and only in a few real-world studies. We recently reported an Italian multicentre 16-week real-life experience in 57 adult patients with moderate-to-severe psoriasis treated with risankizumab. Herein, we report an extension analysis of our study beyond 16 weeks, collecting data on effectiveness of risankizumab on psoriasis characteristics (PASI, PGA, DLQI, NRS itch and NRS pain) after 36- and 52-week treatment. Drug survival rate and safety data were also collected.

This update confirms the excellent tolerability of risankizumab during the whole study period: the ulcerative colitis relapse, well described for anti-IL17 biologics, induced us to discontinue risankizumab. Finally, we underline that the 3 patients who contracted SARS-CoV-2 infection in the whole study period recovered well without interventions continuing risankizumab, as suggested by the Italian data from 12807 patients included in the PSO-BIO-COVID project.

Tagged on:
Accedi all’abstract originale